Updates on Molecular Targeted Therapies for Intraparenchymal CNS Metastases
Central nervous system (CNS) metastases can occur in a high percentage of systemic cancer patients and is a major cause of morbidity and mortality in these patients. Almost any histology can find its way to the brain, but lung, breast, and melanoma are the most common pathologies seen in the CNS fro...
Main Authors: | Akanksha Sharma, Lauren Singer, Priya Kumthekar |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/1/17 |
Similar Items
-
Frontal Intraparenchymal Schwannoma: A Case Report
by: Mitra Rezai, et al.
Published: (2009-08-01) -
Case Report: MSS colorectal extrahepatic (non-liver) metastases as the dominant population for immunotherapy combined with multi-target tyrosine kinase inhibitors
by: Jiayin Liu, et al.
Published: (2023-03-01) -
The role of sunitinib in the therapy of metastatic renal cell carcinoma
by: I. G. Rusakov, et al.
Published: (2020-07-01) -
Recent and Ongoing Research into Metastatic Osteosarcoma Treatments
by: Michael A. Harris, et al.
Published: (2022-03-01) -
Malnutrition and cerebral intraparenchymal damage in patients with thrombosis of dural sinuses and/or cerebral veins
by: Weiwei Xiang, et al.
Published: (2023-12-01)